Abstract
Cells of the growing tumor tissue are exposed to physiological stresses connected with insufficient delivery of oxygen (hypoxia) and accumulation of acidic products of the glycolytic metabolism (acidosis). Adaptation to these microenvironmental stresses involves remodeling of the cellular expression program mediated by hypoxia-inducible factor (HIF), which activates broad array of genes functionally involved in angiogenesis, anaerobic glycolysis, de-adhesion, invasion etc. This leads to increased aggressiveness of tumors, metastatic spread and poor response to therapy. Genes coding for transmembrane carbonic anhydrase (CA) isoforms IX and XII are induced in response to low oxygen as a part of the hypoxic transcriptome. Moreover, CA IX is a direct target of HIF and serves as a surrogate marker of hypoxia and prognostic indicator. Its expression is strongly linked to different types of tumors with the HIF pathway activated due to genetic defect or physiological hypoxia. CA IX (and possibly also CA XII) is participates in pH regulation, which is important for survival of hypoxic cells. Both enzymes are therefore promising therapeutic molecules targetable by inhibitors of CA activity. Some of these sulfonamide compounds and their derivatives are capable to block CA-mediated pH regulation in hypoxia. This review summarizes research data related to distribution, regulation and functional aspects of CA IX and CA XII, and describes emerging possibilities for clinical exploitation of CA inhibitors as imaging tools and anticancer drugs.
Keywords: bicarbonate transport, pH regulation, cancer, hypoxia, Carbonic anhydrase, inhibitor, sulfonamide, anticancer therapy
Current Pharmaceutical Design
Title: Cancer-Associated Carbonic Anhydrases and Their Inhibition
Volume: 14 Issue: 7
Author(s): J. Pastorek, S. Pastorekova and M. Zatovicova
Affiliation:
Keywords: bicarbonate transport, pH regulation, cancer, hypoxia, Carbonic anhydrase, inhibitor, sulfonamide, anticancer therapy
Abstract: Cells of the growing tumor tissue are exposed to physiological stresses connected with insufficient delivery of oxygen (hypoxia) and accumulation of acidic products of the glycolytic metabolism (acidosis). Adaptation to these microenvironmental stresses involves remodeling of the cellular expression program mediated by hypoxia-inducible factor (HIF), which activates broad array of genes functionally involved in angiogenesis, anaerobic glycolysis, de-adhesion, invasion etc. This leads to increased aggressiveness of tumors, metastatic spread and poor response to therapy. Genes coding for transmembrane carbonic anhydrase (CA) isoforms IX and XII are induced in response to low oxygen as a part of the hypoxic transcriptome. Moreover, CA IX is a direct target of HIF and serves as a surrogate marker of hypoxia and prognostic indicator. Its expression is strongly linked to different types of tumors with the HIF pathway activated due to genetic defect or physiological hypoxia. CA IX (and possibly also CA XII) is participates in pH regulation, which is important for survival of hypoxic cells. Both enzymes are therefore promising therapeutic molecules targetable by inhibitors of CA activity. Some of these sulfonamide compounds and their derivatives are capable to block CA-mediated pH regulation in hypoxia. This review summarizes research data related to distribution, regulation and functional aspects of CA IX and CA XII, and describes emerging possibilities for clinical exploitation of CA inhibitors as imaging tools and anticancer drugs.
Export Options
About this article
Cite this article as:
Pastorek J., Pastorekova S. and Zatovicova M., Cancer-Associated Carbonic Anhydrases and Their Inhibition, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877893
DOI https://dx.doi.org/10.2174/138161208783877893 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Platinum Group Antitumor Chemistry: Design and development of New Anticancer Drugs Complementary to Cisplatin
Current Medicinal Chemistry Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Is Brain-Derived Neurotrophic Factor: A Common Link Between Neurodegenerative Disorders and Cancer?
Current Alzheimer Research Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Sphingolipid Signaling Pathways as Potential Therapeutic Targets in Gliomas
Mini-Reviews in Medicinal Chemistry Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine